Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

计划入组 33 人 · 首次发布于 2023 年 7 月 6 日

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

计划入组 14,550 人 · 首次发布于 2023 年 8 月 24 日

A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)

计划入组 18 人 · 首次发布于 2021 年 10 月 7 日

PCSK9 inhibitor (oral, hypercholesterolemia/cardiovascular disease)

PCSK9 inhibitors (oral, cardiovascular diseases/hypercholesterolemia)

PCSK9

Oral-B Laboratories

United States

Philips Oral Healthcare

United States

ORAL RECONSTRUCTION FOUNDATION

United States

FDA Approves Merck's Oral PCSK9 Drug, a First-in-Class Cholesterol Treatment

AstraZeneca's Oral PCSK9 Inhibitor Shows Promise in Phase 1 Trial

Merck Presents Positive Phase 3 Data for Oral PCSK9 Inhibitor Enlicitide at ACC.26